Novavax begins phase 3 trial of NVX-CoV2373 COVID-19 vaccine candidate

Novavax has initiated its first phase 3 clinical trial to assess the efficacy, safety, and immunogenicity of its NVX-CoV2373 COVID-19 vaccine candidate. The US vaccine ... Read More